LRP1B-Related Tumor Genomics and Immunotherapy
Summary
Low-density lipoprotein receptor-related protein 1B (LRP1B) is a member of the low-density lipoprotein receptor family that is frequently altered in diverse malignancies. Acting as a putative tumour suppressor, LRP1B undergoes genetic and epigenetic inactivation in lung, gastric, melanoma and other cancers, and its loss is associated with enhanced genomic instability and elevated tumour mutational burden (TMB). Recent work has shown that LRP1B mutation status shapes the tumour immune microenvironment by modulating immune cell infiltration and neoantigen load. This has direct implications for immune checkpoint blockade, as LRP1B alterations correlate with improved responses to anti-PD-1/PD-L1 therapies in subsets of non-small-cell lung cancer (NSCLC), lung adenocarcinoma and gastric cancer. Beyond mutation profiling, studies of LRP1B structure, ligand binding and regulated proteolysis are illuminating the receptor’s broader roles in cell signalling and immune modulation. Together, these advances position LRP1B as both a biomarker for patient stratification and a potential target for novel immunotherapeutic strategies, with global relevance across tumour types and clinical settings.
Research from Nature Portfolio
No recent Nature Portfolio content available.
LRP1B-Related Tumor Genomics and Immunotherapy publication trend
The graph below shows the total number of articles in lrp1b-related tumor genomics and immunotherapy across all publications each year (not limited to Nature Index journals).
Technical terms
LRP1B: A large cell surface receptor of the low-density lipoprotein receptor family, often inactivated in cancer and implicated in tumour suppression and immune regulation.
Tumour mutational burden (TMB): The total number of somatic mutations per megabase of tumour DNA, used as a predictive biomarker for immunotherapy efficacy.
Immune checkpoint inhibitors (ICIs): Therapeutic antibodies that block inhibitory receptors or ligands on T cells or tumour cells to enhance anti-tumour immunity.
T-cell receptor (TCR) diversity: The range of distinct T-cell receptor sequences within a patient’s T-cell population, reflecting the ability to recognise diverse antigens.
Tumour microenvironment (TME): The diverse cellular and molecular milieu surrounding cancer cells, including immune cells, stromal cells and signalling molecules that influence tumour progression and therapy response.
References
- The combination of tumor mutational burden and T‐cell receptor repertoire predicts the response to immunotherapy in patients with advanced non–small cell lung cancer. MedComm (2024).
- Prognostic Implications of LRP1B and Its Relationship with the Tumor-Infiltrating Immune Cells in Gastric Cancer. Cancers (2023).
- Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy. Frontiers in Immunology (2022).
- LRP1B: A Giant Lost in Cancer Translation. Pharmaceuticals (2021).
- The Putative Tumor Suppressor LRP1B, a Novel Member of the Low Density Lipoprotein (LDL) Receptor Family, Exhibits Both Overlapping and Distinct Properties with the LDL Receptor-related Protein*. Journal of Biological Chemistry (2001).
- Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades. Frontiers in Immunology (2019).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Nature Index 2026 Cancer
Cancer incidence is on the rise. Countries are meeting the challenge in different ways, such as through nationwide action plans and broadening early detection programmes. However, coordinating these efforts to make them accessible, targeted and effective is a balancing act. In this supplement, we explore the factors that are shaping these first lines of defence and the research efforts that are informing them.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.